Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis

Impact · against what's priced in

Immunome's imminent NDA submission for varegacestat and strong Phase 3 efficacy (HR 0.16) provide a concrete near-term catalyst for valuation. The $582.7M cash runway through 2028 further derisks the transition to a multi-asset oncology platform.

IMNM+0.80: No priced-in read yet
In context: The imminent NDA submission and strong Phase 3 data (HR 0.16, ORR 56%) for varegacestat create a clear path to commercialization, while a $582.7M cash position eliminates immediate dilution concerns through 2028.
Read from the article alone

Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis

biotech
IMNM
cancer research
cash runway
nda submission
oncology
phase 3
pipeline

Search tags

Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis

What matters in this story

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis

What matters in this story

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

How each ticker is affected

Connected tickers

Track these names every morning.

Verrica Pharmaceuticals Q3 Earnings Call Highlights

REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy

Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis

What matters in this story

Next reads from the same story arc

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis

What matters in this story

Next reads from the same story arc

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

How each ticker is affected

Connected tickers

Track these names every morning.

Verrica Pharmaceuticals Q3 Earnings Call Highlights

REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy